Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity-Reference-Cited by-同舟云学术

Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity

Published:2012-06 Issue:3 Volume:12 Page:207-214
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Montagna Emilia,Cancello Giuseppe,Bagnardi Vincenzo,Pastrello Davide,Dellapasqua Silvia,Perri Gino,Viale Giuseppe,Veronesi Paolo,Luini Alberto,Intra Mattia,Calleri Angelica,Rampinelli Cristiano,Goldhirsch Aron,Bertolini Francesco,Colleoni Marco

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels;Colleoni;Ann Oncol,2002

2. Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule;Lokich;Cancer Invest,2004

3. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study;Burstein;Paper presented at: 28th Annual San Antonio Breast Cancer Symposium,2005

4. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo;Kim;Nature,1993

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”;Cancer Letters;2024-08

2. Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology;Heliyon;2024-02

3. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer;Breast Cancer Research and Treatment;2023-11-29

4. Low-grade serous ovarian cancer with BRAFV600E mutation treated with metronomic chemotherapy — a case report and literature review;Oncology in Clinical Practice;2023-09-08

5. Xijiao Dihuang decoction relieves the erlotinib-induced dermatitis;Experimental Cell Research;2023-02